{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:01:18Z","timestamp":1784930478387,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873286"],"award-info":[{"award-number":["81873286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["20XD1403500"],"award-info":[{"award-number":["20XD1403500"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["21Y31920400"],"award-info":[{"award-number":["21Y31920400"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.heliyon.2023.e19806","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T02:14:39Z","timestamp":1693620879000},"page":"e19806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress"],"prefix":"10.1016","volume":"9","author":[{"given":"Yirong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-2335","authenticated-orcid":false,"given":"Jiahui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2023.e19806_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19806_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19806_bib3","first-page":"430","article-title":"Current frontline treatment of multiple myeloma","volume":"36","author":"Holstein","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19806_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e19806_bib5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19806_bib6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1535-7163.MCT-04-0338","article-title":"Proteasome inhibitor therapy in multiple myeloma","volume":"4","author":"Chauhan","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19806_bib7","first-page":"171","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19806_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103020","article-title":"Protein quality control in the endoplasmic reticulum and cancer","volume":"19","author":"Moon","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19806_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040632","article-title":"Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma","volume":"11","author":"Khaled","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2023.e19806_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5729710","article-title":"The role of the ER-induced UPR pathway and the efficacy of its inhibitors and inducers in the inhibition of tumor progression","volume":"2019","author":"Walczak","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19806_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19806_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/10428190902895780","article-title":"Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells","volume":"50","author":"Dong","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"6059","key":"10.1016\/j.heliyon.2023.e19806_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.heliyon.2023.e19806_bib14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","article-title":"Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma","volume":"133","author":"Zhuang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e19806_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110005","article-title":"Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4\/CHOP pathway in multiple myeloma","volume":"125","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e19806_bib16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3389\/fonc.2019.01530","article-title":"Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78","volume":"9","author":"Borjan","year":"2019","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19806_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102341","article-title":"Pharmacological or TRIB3-mediated suppression of ATF4 transcriptional activity promotes hepatoma cell resistance to proteasome inhibitor bortezomib","volume":"13","author":"Ord","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19806_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000518936","article-title":"miR-466 contributes to the enhanced antitumor effect of bortezomib on non-small-cell lung cancer by inhibiting CCND1","volume":"67","author":"Wang","year":"2022","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19806_bib19","first-page":"167","article-title":"Safety of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.heliyon.2023.e19806_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109249","article-title":"Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response","volume":"118","author":"Lin","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19806_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41420-022-00950-5","article-title":"GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19806_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The unfolded protein response and cell fate control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol. Cell."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19806_bib23","doi-asserted-by":"crossref","first-page":"a013169","DOI":"10.1101\/cshperspect.a013169","article-title":"Endoplasmic reticulum stress sensing in the unfolded protein response","volume":"5","author":"Gardner","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19806_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2016.06.007","article-title":"Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance","volume":"30","author":"Cerezo","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2023.e19806_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mce.2018.02.010","article-title":"The GRP78\/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways","volume":"474","author":"Ruggiero","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19806_bib26","article-title":"Targeted inhibition of GRP78 by HA15 promotes apoptosis of lung cancer cells accompanied by ER stress and autophagy","volume":"9","author":"Wu","year":"2020","journal-title":"Biol. Open"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19806_bib27","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19806_bib28","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1074\/jbc.REV118.002804","article-title":"The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: getting by with a little help from ERdj friends","volume":"294","author":"Pobre","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19806_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/scdb.1999.0318","article-title":"Role and regulation of the ER chaperone BiP","volume":"10","author":"Gething","year":"1999","journal-title":"Semin. Cell Dev. Biol."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e19806_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164173","article-title":"Direct endoplasmic reticulum targeting by the selective alkylphospholipid analog and antitumor ether lipid edelfosine as a therapeutic approach in pancreatic cancer","volume":"13","author":"Mollinedo","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19806_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1083\/jcb.201003138","article-title":"Regulation of basal cellular physiology by the homeostatic unfolded protein response","volume":"189","author":"Rutkowski","year":"2010","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19806_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00018-013-1490-2","article-title":"Regulatory crosstalk within the mammalian unfolded protein response","volume":"71","author":"Brewer","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.heliyon.2023.e19806_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8384913","article-title":"Modulation of ERQC and ERAD: a broad-spectrum spanner in the works of cancer cells?","volume":"2019","author":"Tax","year":"2019","journal-title":"J. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19806_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061222","article-title":"Physiological roles of the autoantibodies to the 78-kilodalton glucose-regulated protein (GRP78) in cancer and autoimmune diseases","volume":"10","author":"Gonzalez-Gronow","year":"2022","journal-title":"Biomedicines"},{"issue":"17","key":"10.1016\/j.heliyon.2023.e19806_bib35","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-15-3111","article-title":"A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement","volume":"22","author":"Rasche","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19806_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111787","article-title":"Cell surface GRP78 as a death receptor and an anticancer drug target","volume":"11","author":"Ge","year":"2019","journal-title":"Cancers"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023070147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023070147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:06:39Z","timestamp":1784927199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023070147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2405844023070147"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19806","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e19806"}}